Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1993 1
2000 1
2002 1
2003 1
2004 1
2005 1
2006 2
2007 1
2008 2
2009 3
2010 7
2011 5
2012 5
2013 2
2014 5
2015 3
2016 10
2017 6
2018 9
2019 11
2020 13
2021 21
2022 17
2023 22
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

140 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Mäenpää J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Moore KN, et al. Among authors: willmott l. J Clin Oncol. 2021 Jun 10;39(17):1842-1855. doi: 10.1200/JCO.21.00306. Epub 2021 Apr 23. J Clin Oncol. 2021. PMID: 33891472 Free PMC article. Clinical Trial.
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Pignata S, Bookman M, Sehouli J, Miller A, Penson RT, Taskiran C, Anderson C, Hietanen S, Myers T, Madry R, Willmott L, Lortholary A, Thomes-Pepin J, Aghajanian C, McCourt C, Stuckey A, Wu X, Nishio S, Copeland LJ, He Y, Molinero L, Patel S, Lin YG, Khor VK, Moore KN. Pignata S, et al. Among authors: willmott l. Gynecol Oncol. 2023 Oct;177:20-31. doi: 10.1016/j.ygyno.2023.06.018. Epub 2023 Aug 23. Gynecol Oncol. 2023. PMID: 37625235 Clinical Trial.
Charlie Gard: in defence of the law.
Close E, Willmott L, White BP. Close E, et al. Among authors: willmott l. J Med Ethics. 2018 Jul;44(7):476-480. doi: 10.1136/medethics-2017-104721. Epub 2018 May 3. J Med Ethics. 2018. PMID: 29724811 Review.
Institutional objection to abortion: A mixed-methods narrative review.
Merner B, Haining CM, Willmott L, Savulescu J, Keogh LA. Merner B, et al. Among authors: willmott l. Womens Health (Lond). 2023 Jan-Dec;19:17455057231152373. doi: 10.1177/17455057231152373. Womens Health (Lond). 2023. PMID: 36785871 Free PMC article. Review.
Surrogacy: ill-conceived rights.
Willmott L. Willmott L. J Law Med. 2002 Nov;10(2):198-220. J Law Med. 2002. PMID: 12497735 Review.
Physician attitudes to voluntary assisted dying: a scoping review.
Rutherford J, Willmott L, White BP. Rutherford J, et al. Among authors: willmott l. BMJ Support Palliat Care. 2021 Jun;11(2):200-208. doi: 10.1136/bmjspcare-2020-002192. Epub 2020 Jun 20. BMJ Support Palliat Care. 2021. PMID: 32563993 Review.
140 results